Therapy for HIV Patients Failing Previous Therapy

In preclinical studies, the non-nucleoside reverse transcriptase inhibitor (NNRTI) capravirine demonstrated a potent antiviral activity against wild-type HIV as well as HIV strains with mutations in reverse transcriptase, such as K103N, that confer broad viral resistance to other NNRTIs to which patients failing treatment may have been exposed.

In clinical studies of treatment-naive patients, capravirine showed antiretroviral activity when used alone for a short period of time, and achieved target antiretroviral concentrations in plasma as a part of a combination therapy. A new double-blind 48-week study will evaluate capravirine for use in two groups of HIV-infected patients: those who have never been treated with anti-HIV medications and those who have failed previous treatment. Capravirine, which has been generally well tolerated by patients, was developed by Agouron Pharmaceuticals, Inc. (Toronto, Canada).



Related Links:
Agouron Pharmaceuticals